Abstract：Objective:To investigate the effects of uterine artery embolization on the levels of estradiol luteinizing hormone and follicle stimulating hormone in postpartum hemorrhage patients. Methods: 60 patients with postpartum hemorrhage admitted to our hospital from January 2016 to December 2018 were divided into two groups according to whether the patients received uterine artery embolization. The patients in group A were treated with uterine artery embolization, while those in group B were treated with non-uterine artery embolization. The amount of postpartum hemorrhage and hospital stay in 24 hours were recorded. The ICU occupancy rate, hysterectomy rate, puerperal infection rate and postpartum hemorrhage rate were compared between the two groups. The changes of follicle-stimulating hormone, luteinizing hormone and estradiol levels before and after treatment were analyzed. Results: There was no significant difference in hospital stay between the two groups (t=0.625, P>0.05). Postpartum hemorrhage within 24 hours in group a was (1039.28±53.44) ml, significantly lower than that in group b (2734.39±43.29) ml (t=6.283, P<0.05). There was no significant difference in puerperal infection rate between the two groups (P>0.05). The ICU occupancy rate, uterine resection rate and postpartum hemorrhage rate in group a were 43.75%, 0 and 46.88%, respectively, lower than those in group b 78.57%, 7.14% and 85.71% (t=10.282, t=5.394, t=11.283, all P<0.05). There were no significant differences in the levels of follicular maturation hormone, luteinizing hormone and estradiol between the two groups before treatment (all P>0.05). After treatment, the levels of follicle-stimulating hormone, luteinizing hormone and estradiol in group a were significantly higher than those in group b (t=3.293, t=4.383, t=5.384, all P<0.05). Conclusion: Uterine artery embolization for postpartum hemorrhage patients can effectively improve the therapeutic effect, and will not have a greater impact on ovarian function, follicle-stimulating hormone, luteinizing hormone and estradiol levels. It is worthy of clinical application.
[1] Shingai N, Harada Y, Iizuka H, et al. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes[J]. Int Hematol, 2018,108(6):598~606. [2] 梁海平.子宫动脉栓塞术治疗子宫肌瘤的围术期护理方法探讨[J].河北医学,2016,22(10):1721~1722. [3] Sanz-De PM, Wang W, Kanagal-Shamanna R, et al. Myelodysplastic syndromes: laboratory workup in the context of new concepts and classification criteria[J]. Curr Hematol Malig Rep, 2018,13(6):467~476. [4] 苏继颖,杨华,梁致怡,等.妊娠中期孕妇中央性前置胎盘的诊断及引产方法(附69例分析)[J].山东医药,2017,57(3):58~60. [5] Short NJ, Jabbour E, Naqvi K, et al. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents[J]. Am Hematol, 2019,94(1):74~79. [6] 高梦涵,胡勇.中止妊娠前子宫动脉栓塞术预防宫内大出血应用价值[J].介入放射学杂志,2016,25(5):443~447. [7] Narayanan S. Managing anaemia in bone marrow failure syndromes[J]. Curr Opin Support Palliat Care, 2018,12(4):538~541. [8] 杨琼,黄强.6例子宫角胎盘植入的临床治疗分析[J].检验医学与临床,2018,15(8):1153~1155. [9] Duetz C, Westers TM, van de Loosdrecht AA. Clinical implication of multi-parameter flow cytometry in myelodysplastic syndromes[J]. Pathobiology, 2018,85(5-6):274~283.
2019, Vol. 25 
冀公网安备13080202000677号